Clinical Trials
43 trialsFirmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Peking University Cancer Hospital & Institute
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Fudan University
TROP-LUNG
Tianjin Medical University Cancer Institute and Hospital
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
Shanghai Pulmonary Hospital, Shanghai, China
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Guangzhou University of Traditional Chinese Medicine
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
Jiangmen Central Hospital
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
Hunan Cancer Hospital
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Tianjin Medical University Cancer Institute and Hospital
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Peking Union Medical College
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
Fudan University
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Fudan University
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Peking University Cancer Hospital & Institute
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Peking Union Medical College Hospital
PIKACHU
Hunan Province Tumor Hospital
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
Hunan Province Tumor Hospital
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Hunan Province Tumor Hospital
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Changhai Hospital
LungBrain001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Tang-Du Hospital
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Sichuan Cancer Hospital and Research Institute
SELECT-2
Hangzhou Normal University
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage â…¡-â…¢B EGFR Sensitive Mutant NSCLC
Shanghai Zhongshan Hospital
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
First Affiliated Hospital of Zhejiang University
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
Peking Union Medical College Hospital
FOCUS-A
Shanghai Chest Hospital
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Chongqing University Cancer Hospital
FOCUS-C
Sun Yat-sen University
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
Fudan University
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
ATHEM
Tongji University
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Peking University People's Hospital
TERMGGO
Ruijin Hospital
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
Sun Yat-sen University
Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
Tianjin Medical University Cancer Institute and Hospital